CRVS insider filings
Corvus Pharmaceuticals, Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-11-13. Screen CRVS transaction legs live →
Insider transaction summary — last 90 days
2026-08-23 to 2026-11-21, from the filings listed below: 1 insider filing (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 4 legs across 1 filing by 1 insider — 4,500 shares, $50,475 total (shares × price as filed).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 0.
- Largest priced transaction: purchase of 3,000 shares @ $11.46 ($34,381) by Arcara Jeffrey, filed 2026-11-13.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Arcara Jeffrey — Chief Business Officer | 1 | 4 legs · 4,500 sh · $50,475 | — | — |
Recent insider filings — Corvus Pharmaceuticals, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-13 | 4 | Arcara Jeffrey — Chief Business Officer | Purchase (P): 3,000 @ $11.46 · Purchase (P): 497 @ $11.12 · Purchase (P): 503 @ $10.37 · Purchase (P): 500 @ $10.71 | EDGAR |
| 2026-06-15 | 4 | Moore David Scott — Director | Purchase (P): 21,700 @ $11.53 · Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2026-06-15 | 4 | van den Broek Richard — Director | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2026-06-15 | 4 | Grais Linda — Director | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2026-06-15 | 4 | Thompson Peter A. — Director, 10% owner | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2026-06-15 | 4 | CLARK IAN T — Director | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2026-05-20 | 4 | MILLER RICHARD A MD — President and CEO, Director | Purchase (P): 5,000 @ $12.05 · Purchase (P): 1,932 @ $12.01 | EDGAR |
| 2026-04-27 | 4 | Chan Andrew C. — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2026-01-30 | 4 | Thompson Peter A. — Director, 10% owner | Option exercise (M): 30,000 @ $15 · Option exercise (M): 15,000 @ $9.70 · Option exercise (M): 15,000 @ $12.50 · Option exercise (M): 15,000 @ $3.61 · Option exercise (M): 15,000 @ $2 · Option exercise (M): 15,000 @ $3.27 · +20 more | EDGAR |
| 2025-12-08 | 4 | Jones William Benton — See Remarks | Grant/award (A): 400,000 (derivative) @ $0 | EDGAR |
| 2025-12-08 | 4 | Arcara Jeffrey — Chief Business Officer | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2025-12-08 | 4 | LEA LEIV — Chief Financial Officer | Grant/award (A): 400,000 (derivative) @ $0 | EDGAR |
| 2025-12-08 | 4 | MILLER RICHARD A MD — President and CEO, Director | Grant/award (A): 1,000,000 (derivative) @ $0 | EDGAR |
| 2025-10-06 | 4 | Moore David Scott — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2025-07-01 | 4 | Thompson Peter A. — Director, 10% owner | Option exercise/expiry (X): 1,397,684 @ $3.50 · Sale (S): 1,176,332 @ $4.16 · Option exercise/expiry (X): 1,397,684 (derivative) @ $0 | EDGAR |
| 2025-07-01 | 4 | ORBIMED ADVISORS LLC — Director, 10% owner OrbiMed Capital GP V LLC — Director, 10% owner | Option exercise/expiry (X): 1,397,684 @ $3.50 · Sale (S): 1,176,332 @ $4.16 · Option exercise/expiry (X): 1,397,684 (derivative) @ $0 | EDGAR |
| 2025-06-16 | 4 | Morrison Scott W — Director | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2025-06-16 | 4 | Grais Linda — Director | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2025-06-16 | 4 | Thompson Peter A. — Director, 10% owner | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2025-06-16 | 4 | CLARK IAN T — Director | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | Jones William Benton — See Remarks | Option exercise (M): 19,357 @ $3.50 · Option exercise (M): 19,357 (derivative) | EDGAR |
| 2025-05-09 | 4 | MILLER RICHARD A MD — President and CEO, Director | Option exercise (M): 559,073 @ $3.50 · Option exercise (M): 559,073 (derivative) | EDGAR |
| 2025-04-09 | 4 | van den Broek Richard — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2024-12-23 | 4 | Arcara Jeffrey — Chief Business Officer | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2024-12-23 | 4 | Jones William Benton — See Remarks | Grant/award (A): 300,000 (derivative) @ $0 | EDGAR |
| 2024-12-23 | 4 | LEA LEIV — Chief Financial Officer | Grant/award (A): 300,000 (derivative) @ $0 | EDGAR |
| 2024-12-23 | 4 | MILLER RICHARD A MD — President and CEO, Director | Grant/award (A): 750,000 (derivative) @ $0 | EDGAR |
| 2024-06-17 | 4 | Morrison Scott W — Director | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2024-06-17 | 4 | Gould Terry P — Director, 10% owner | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2024-06-17 | 4 | Grais Linda — Director | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2024-06-17 | 4 | Thompson Peter A. — Director, 10% owner | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2024-06-17 | 4 | CLARK IAN T — Director | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2024-05-14 | 4 | MILLER RICHARD A MD — President and CEO, Director | Gift (G): 302,016 @ $0 | EDGAR |
| 2024-05-08 | 4 | Thompson Peter A. — Director, 10% owner | Purchase (P): 1,444,085 (derivative) @ $1.73 · Purchase (P): 1,397,684 (derivative) | EDGAR |
| 2024-05-08 | 4 | ORBIMED ADVISORS LLC — Director, 10% owner OrbiMed Capital GP V LLC — Director, 10% owner | Purchase (P): 1,444,085 (derivative) @ $1.73 · Purchase (P): 1,397,684 (derivative) | EDGAR |
| 2024-05-07 | 4 | Jones William Benton — See Remarks | Purchase (P): 20,000 @ $1.73 · Purchase (P): 19,357 (derivative) | EDGAR |
| 2024-05-07 | 4 | MILLER RICHARD A MD — President and CEO, Director | Purchase (P): 577,634 @ $1.73 · Purchase (P): 559,073 (derivative) | EDGAR |
| 2024-03-01 | 4 | Arcara Jeffrey — Chief Business Officer | Grant/award (A): 400,000 (derivative) @ $0 | EDGAR |
| 2023-12-08 | 4 | LEA LEIV — Chief Financial Officer | Grant/award (A): 200,000 (derivative) @ $0 | EDGAR |
| 2023-12-08 | 4 | Jones William Benton — See Remarks | Grant/award (A): 200,000 (derivative) @ $0 | EDGAR |
| 2023-12-08 | 4 | Morrison Scott W — Director | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2023-12-08 | 4 | Gould Terry P — Director, 10% owner | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2023-12-08 | 4 | Mitchell Edith P. — Director | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2023-12-08 | 4 | Grais Linda — Director | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2023-12-08 | 4 | Thompson Peter A. — Director, 10% owner | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2023-12-08 | 4 | CLARK IAN T — Director | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2023-12-08 | 4 | MILLER RICHARD A MD — President and CEO, Director | Grant/award (A): 500,000 (derivative) @ $0 | EDGAR |
| 2023-06-20 | 4 | Grais Linda — Director | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2023-06-20 | 4 | Thompson Peter A. — Director, 10% owner | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2023-06-20 | 4 | CLARK IAN T — Director | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — Corvus Pharmaceuticals, Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-11-05 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-22 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-06-12 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-14 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-07 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-23 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-03-13 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-23 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=CRVS returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs